Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ)
CNY 60.51
(0.51%)
CNY 60.51
(0.51%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 689.01 Million CNY | 8.44% |
| 2022 | 635.39 Million CNY | 82.72% |
| 2021 | 347.74 Million CNY | 100.72% |
| 2020 | 173.24 Million CNY | 51.32% |
| 2019 | 114.48 Million CNY | -3.29% |
| 2018 | 118.37 Million CNY | 37.05% |
| 2017 | 86.37 Million CNY | -70.94% |
| 2016 | 297.22 Million CNY | 9.03% |
| 2015 | 272.61 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 532.48 Million CNY | -11.35% |
| 2024 Q1 | 600.64 Million CNY | -12.83% |
| 2024 Q3 | 496 Million CNY | -6.85% |
| 2023 Q4 | 689.01 Million CNY | 28.5% |
| 2023 FY | 689.01 Million CNY | 8.44% |
| 2023 Q2 | 547.37 Million CNY | -3.79% |
| 2023 Q1 | 568.94 Million CNY | -10.46% |
| 2023 Q3 | 536.18 Million CNY | -2.05% |
| 2022 Q2 | 410.11 Million CNY | 37.55% |
| 2022 FY | 635.39 Million CNY | 82.72% |
| 2022 Q4 | 635.39 Million CNY | 56.84% |
| 2022 Q3 | 405.12 Million CNY | -1.22% |
| 2022 Q1 | 298.16 Million CNY | -14.26% |
| 2021 Q4 | 347.74 Million CNY | 118.53% |
| 2021 FY | 347.74 Million CNY | 100.72% |
| 2021 Q3 | 159.12 Million CNY | -15.28% |
| 2021 Q1 | 125.38 Million CNY | -27.63% |
| 2021 Q2 | 187.83 Million CNY | 49.8% |
| 2020 Q2 | 147.9 Million CNY | 47.74% |
| 2020 Q1 | 100.11 Million CNY | -12.56% |
| 2020 FY | 173.24 Million CNY | 51.32% |
| 2020 Q3 | 187.03 Million CNY | 26.46% |
| 2020 Q4 | 173.24 Million CNY | -7.37% |
| 2019 Q1 | - CNY | -100.0% |
| 2019 Q4 | 114.48 Million CNY | 0.0% |
| 2019 FY | 114.48 Million CNY | -3.29% |
| 2018 Q3 | 148.88 Million CNY | 0.0% |
| 2018 Q4 | 118.37 Million CNY | -20.49% |
| 2018 FY | 118.37 Million CNY | 37.05% |
| 2017 FY | 86.37 Million CNY | -70.94% |
| 2016 FY | 297.22 Million CNY | 9.03% |
| 2015 FY | 272.61 Million CNY | 0.0% |